KRYS
Krystal Biotech, Inc.
NASDAQ · Healthcare · Biotechnology · US
$320.25
+1.16%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$320.30
From 52W high−15.31%
Volume206948.00
Market cap$9.48B
P/E (TTM)38.7x
P/S (TTM)21.5x
Div yield—
Key dataOct 19, 2026
Open
$320.30
From 52W high
−15.31%
Volume
206948.00
Market cap
$9.48B
ValuationView details →
P/E (Fwd)
37.1x
EV/EBITDA
39.3x
P/E (TTM)
38.7x
RSI (14)
41.5
MomentumView details →
1D Return
+1.16%
YTD Return
+29.73%
SummaryUpdated Jun 1, 2026
Krystal Biotech, Inc. (NASDAQ:KRYS) is a biotechnology company founded in 2015 and headquartered in Pittsburgh, Pennsylvania. The company specializes in developing redosable gene therapies for rare diseases, with a particular focus on dermatological conditions. Krystal achieved a significant milestone in 2023 when it became the first company to receive FDA approval for a redosable gene therapy with its lead product VYJUVEK (beremagene geperpavec or B-VEC) for treating dystrophic epidermolysis bullosa. The company has successfully transitioned from a clinical-stage biotechnology firm to a profitable commercial enterprise, generating nearly $291 million in revenue in 2024 from VYJUVEK sales alone.
Similar companies
Latest newsMore news →
Krystal Biotech announced positive clinical data for KB113 in three patients with Gorlin syndrome, reporting regression in over 80% of assessed basal cell carcinoma lesions and histologically confirmed clearance of an injected lesion in each patient.4d agoKrystal Biotech reported financial results for the second quarter ended June 30, 2026, with $119.2 million in global VYJUVEK revenue and $1.1 billion in cash and investments.77d ago